Clinical trial NCT00542971 (phase 1/phase 2, status: completed)
Conditions: aml, acute myeloid leukemia, myelodysplastic disorders
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: idarubicin, sorafenib, ara-c
SMILES: [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of 1) AML (World Health Organization classification definition of > 20%
             blasts), or 2) high risk MDS (defined as the presence of > 10% blasts).

          2. Patients aged 15 to 60 years are eligible. Patients older than 60 who are deemed fit
             to receive intensive chemotherapy by the treating physician are eligible after
             discussion with the Principal Investigator (PI). For the Phase II portion of the
             study, patients must be chemo-naïve, i.e. not have received any prior chemotherapy
             (except hydrea) for AML or MDS. They could have received hypomethylator agents,
             transfusions, hematopoietic growth factors or vitamins. Temporary prior measures such
             as pheresis or hydrea are allowed. In the Phase I portion, patients with relapsed or
             refractory AML/MDS are also eligible.

          3. Serum biochemical values with the following limits unless considered due to leukemia:
             1) creatinine less than or equal to 2 mg/dl, 2) total bilirubin less than or equal to
             2 mg/dL, unless increase is due to hemolysis or congenital disorder, and 3)
             transaminases (SG PT) less than or equal to 2.5 times upper limit of normal (ULN)

          4. Ability to take oral medication.

          5. Ability to understand and provide signed informed consent.

          6. Baseline test of ejection fraction must be >/=50%.

          7. Performance status < 3, unless directly related to the disease process as determined
             by the principal investigator.

        Exclusion Criteria:

          1. Patients with Acute promyelocytic leukemia (APL).

          2. Any coexisting medical condition that in the judgment of the treating physician is
             likely to interfere with study procedures or results.

          3. Nursing women, women of childbearing potential with positive urine pregnancy test, or
             women of childbearing potential who are not willing to maintain adequate contraception
             (such as birth control pills, Intrauterine Device (IUD), diaphragm, abstinence, or
             condoms by their partner) over the entire course of the study.

          4. Any significant, uncontrolled hypertension.

          5. Cardiac disease: Congestive heart failure > class II The New York Heart Association
             (NYHA). Patients must not have unstable angina (anginal symptoms at rest) or new onset
             angina (began within the last 3 months) or myocardial infarction within the past 6
             months.

          6. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy. Sorafenib is
             contraindicated in patients with known severe hypersensitivity to sorafenib or any of
             the excipients.

          7. Known human immunodeficiency virus (HIV) infection or active Hepatitis B or C.

          8. Thrombotic or embolic events such as a cerebrovascular accident including transient
             ischemic attacks within the past 6 months.

          9. Pulmonary hemorrhage/bleeding event > or = to Common Terminology Criteria for Adverse
             Events (CTCAE) Grade 2 within 4 weeks of first dose of study drug.

         10. Any other hemorrhage/bleeding event > or = to CTCAE Grade 3 within 4 weeks of first
             dose of study drug.

         11. Major surgery, open biopsy or significant traumatic injury within 4 weeks of first
             study drug.

         12. Use of St. John's Wort or rifampin.

         13. Known or suspected allergy to sorafenib or any agent given in the course of this
             trial.

         14. Active clinically serious and uncontrolled infection > CTCAE Grade 2

         15. Serious non-healing wound, ulcer, or bone fracture